Digital Mammography Product Comparison Report 2014
BOTTOM LINES Women’s Imaging 2013: Measuring the Options
FUJIFILMÂ
ClearView-CSm great for budget-conscious providers. Competitive with field service and reliability. However, many customers desire more recent platform of digital mammography and tomosynthesis and a partnership with Hologic. Only 19% would start with Fuji if they could start again. Early adopters of AspireHD pleased so far–overall performance far ahead of that of ClearView-CSm with eight-point gap.Â
GE HEALTHCAREÂ
Excellent field engineers and support coverage. Customers feel GE is slow on deliv - ering tomosynthesis—losing some market share to Hologic. Lack of parts availability causing extended downtime. The somo•v INSIGHT whole breast ultrasound recently added, rounding out GE’s breast imaging portfolio. The somo•v INSIGHT has great image quality and patient comfort. Lack of adequate reimbursement for screening breast ultrasound is barrier for use.Â
HOLOGICÂ
Top performer in 2D digital mammography. Dedicated to women’s imaging and development of new technology; providers feel Hologic is a partner. Implementations and training top notch. Some customers live more than three years report reliability issues.Â
SIEMENSÂ
Inspiration big improvement over prior system NovationDR. Better image quality and functionality. Automated compression feature, Opcomp, and paddle options improve workflow and patient comfort. Competes with Hologic on 2D mammography, but customers still want tomosynthesis, which is live for Siemens customers in Europe. Implementations have room to improve. Automated whole breast ultrasound, AVBS, leverages the general use of the ACUSON S2000 and S3000. Â
Project Manager
Robert Ellis
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.